ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
lorlatinib Sensitive: A2 - Guideline
|
lorlatinib Sensitive: A2 - Guideline
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
ALK inhibitor Sensitive: A2 - Guideline
|
ALK inhibitor Sensitive: A2 - Guideline
|
ALK fusion
|
Melanoma
|
ALK fusion
|
Melanoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ALK fusion
|
Melanoma
|
ALK fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
brigatinib Sensitive: A2 - Guideline
|
brigatinib Sensitive: A2 - Guideline
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
alectinib Sensitive: A2 - Guideline
|
alectinib Sensitive: A2 - Guideline
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
crizotinib Sensitive: B - Late Trials
|
crizotinib Sensitive: B - Late Trials
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
alectinib Sensitive: C2 – Inclusion Criteria
|
alectinib Sensitive: C2 – Inclusion Criteria
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
anlotinib Sensitive: C3 – Early Trials
|
anlotinib Sensitive: C3 – Early Trials
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
ceritinib Sensitive: C3 – Early Trials
|
ceritinib Sensitive: C3 – Early Trials
|
ALK fusion
|
Colorectal Adenocarcinoma
|
ALK fusion
|
Colorectal Adenocarcinoma
|
ceritinib Sensitive: C3 – Early Trials
|
ceritinib Sensitive: C3 – Early Trials
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
pemetrexed Resistant: C3 – Early Trials
|
pemetrexed Resistant: C3 – Early Trials
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
bevacizumab + alectinib Sensitive: C3 – Early Trials
|
bevacizumab + alectinib Sensitive: C3 – Early Trials
|
ALK fusion
|
Lung Cancer
|
ALK fusion
|
Lung Cancer
|
crizotinib Resistant: C3 – Early Trials
|
crizotinib Resistant: C3 – Early Trials
|
ALK fusion
|
LUAD
|
ALK fusion
|
LUAD
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
ALK fusion
|
Glioma
|
ALK fusion
|
Glioma
|
lorlatinib Sensitive: C4 – Case Studies
|
lorlatinib Sensitive: C4 – Case Studies
|
ALK fusion
|
Triple Negative Breast Cancer
|
ALK fusion
|
Triple Negative Breast Cancer
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
ALK fusion
|
T Cell Non-Hodgkin Lymphoma
|
ALK fusion
|
T Cell Non-Hodgkin Lymphoma
|
gilteritinib Sensitive: D – Preclinical
|
gilteritinib Sensitive: D – Preclinical
|